KRAS and colorectal cancer: The investigation found that when this combination drug therapy was applied to two colorectal cancer cells carrying both β-catenin and the KRAS mutation, the Ls174T cells showed inhibition of MAPK signaling while the DLD-1 cells inhibited FOS expression, which downregulates RalA [149].